Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing

Experts discuss whether providers should wait for another complete scientific statement from the National Lipid Association (NLA) or new guidelines from organizations like the American Heart Association (AHA) before implementing the 2024 NLA recommendation for universal lipoprotein(a) (Lp[a]) measurement.

EP: 1.Lp(a) in ASCVD and Guideline Recommendations

EP: 2.Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis

EP: 3.The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis

EP: 4.Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease

EP: 5.Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime

EP: 6.How the Genetic Nature of Lp(a) Levels Influences Screening

EP: 7.A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk

EP: 8.The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations

EP: 9.Evidence Supporting 2024 Guidance for Lp(a) Testing

EP: 10.Factoring Cost, Recommendations, and Evidence Into Formulary Decisions about Lp(a) Testing

Now Viewing

EP: 11.Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing

Video content above is prompted by the following:

The NLA’s 2024 recommendation comes as a “focused update” to its 2019 scientific statement on the use of Lp(a) in clinical practice. Should providers wait for another complete scientific statement from NLA—or for new guidelines from AHA or other organizations—before implementing this recommendation?

Related Videos

Related Content

Advertisement

April 18th 2025

"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health

Kyle Munz Antoine Keller, MD, FACC, FACS

Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

April 4th 2025

High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment

Giuliana Grossi Christian Ruff, MD John Buse, MD, PhD Marc P. Bonaca, MD, MPH Marc Humbert, MD, PhD Jawad Haider Butt, MD, PhD Siddharth M. Patel, MD, MPH

Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.

May 10th 2022

For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management

On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.

March 24th 2025

Raising Awareness of Lp(a) to Improve Heart Disease Treatment Approaches

Kyle Munz Nathan Wong, PhD

Lipoprotein(a) [Lp(a)] plays a key role in assessing cardiovascular risk, making awareness efforts equally essential for prevention and early intervention.

March 21st 2025

FDA Approves Vutrisiran to Mitigate Cardiomyopathy-Related Risks and Conditions

Kyle Munz

In a recent decision, the FDA approved vutrisiran (amvuttra), making it the only approved therapy for adults with hereditary transthyretin-mediated amyloidosis (ATTR-CM) or wild-type cardiomyopathy.

Related Content

Advertisement

April 18th 2025

"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health

Kyle Munz Antoine Keller, MD, FACC, FACS

Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

April 4th 2025

High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment

Giuliana Grossi Christian Ruff, MD John Buse, MD, PhD Marc P. Bonaca, MD, MPH Marc Humbert, MD, PhD Jawad Haider Butt, MD, PhD Siddharth M. Patel, MD, MPH

Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.

May 10th 2022

For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management

On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.

March 24th 2025

Raising Awareness of Lp(a) to Improve Heart Disease Treatment Approaches

Kyle Munz Nathan Wong, PhD

Lipoprotein(a) [Lp(a)] plays a key role in assessing cardiovascular risk, making awareness efforts equally essential for prevention and early intervention.

March 21st 2025

FDA Approves Vutrisiran to Mitigate Cardiomyopathy-Related Risks and Conditions

Kyle Munz

In a recent decision, the FDA approved vutrisiran (amvuttra), making it the only approved therapy for adults with hereditary transthyretin-mediated amyloidosis (ATTR-CM) or wild-type cardiomyopathy.